PRESS RELEASE
News
-
-
PRESS RELEASE
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
Abivax updates obefazimod Phase 2b clinical program in Crohn’s disease following FDA feedback. Trial design modification to align with FDA recommendations. Patient enrollment to start in Q3 2024 -
PRESS RELEASE
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.12.23.
ABIVAX annonce le nombre d'actions et de droits de vote au 31.12.2023 conformément aux réglementations en vigueur. La société est spécialisée en biotechnologie et développe des traitements thérapeutiques pour les maladies inflammatoires chroniques -
-
PRESS RELEASE
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
Abivax, a clinical-stage biotechnology company, will host a virtual KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with ulcerative colitis on February 6, 2024. The event will feature discussions on the unmet medical need, current treatment landscape, and ongoing clinical development plans for obefazimod. The key speakers at the event will be Marla Dubinsky, MD, and Parambir Dulai, MD, who are both consultants for Abivax and members of the Steering Committee for the IBD Program. -
PRESS RELEASE
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
Abivax, a clinical-stage biotechnology company, provides its 2024 strategic outlook and key milestones, including the expected data read-outs and trial results for its lead drug candidate obefazimod in the treatment of ulcerative colitis and Crohn’s disease. The company also outlines its financial update and objectives for strengthening its product pipeline. Learn more about Abivax's priorities and milestones for 2024. -
PRESS RELEASE
Abivax: Perspectives stratégiques d’Abivax pour 2024 et principales étapes au cours des 12 prochains mois
Abivax annonce ses perspectives stratégiques pour 2024 et les principales étapes des 12 prochains mois, y compris la publication des premiers résultats des essais d'induction du programme pivot ABTECT de phase 3 -
-
-
